Corporate ProfileCytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.
Stock InformationNASDAQ: CTMX$26.57 Stock is Down 0.44 (1.63%)
Recent Webcast
03/15/18 8:30 a.m. ET
CytomX Therapeutics Inc at the Barclay’s Global Health Conference
Recent Presentation
Download Documentation CTMX Corporate Presentation March 2018
Recent News

More >>

Data provided by Nasdaq. Minimum 15 minutes delayed.